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Abstract 
Estonia has one the highest number of new HIV diagnoses in the European Union, mainly 
among injecting drug users and heterosexuals. Little is known of HIV incidence, which is 
crucial for limiting the spread of the epidemic. Using a Recent HIV Testing Algorithm (RITA) 
assay, we aimed to estimate HIV incidence in 2013.  
All individuals aged ≥18 years newly-diagnosed with HIV in Estonia January- December 2013, 
except blood donors and those undergoing antenatal screening, were included. Demographic 
and clinical data were obtained from the Estonian Health Board and the Estonian HIV-positive 
patient database. Serum samples were tested for recent infection using the LAg-avidity EIA 
assay. HIV incidence was estimated based on previously published methods. 
Of 69,115 tested subjects, 286 (0.41%) were newly-diagnosed with HIV with median age of 
33 years (IQR 28-42) and 65% male. Self-reported routes of HIV transmission were mostly 
sex between men and women (n=157, 54%) and injecting drug use (n=62, 21%); 64 (22%) 
were with unknown risk group. Eighty two (36%) were assigned recent, resulting in estimated 
HIV incidence of 0.06%, corresponding to 642 new infections in 2013 among the non-screened 
population. Incidence was highest (1.48%) among people who inject drugs. 
These high HIV incidence estimates in Estonia call for urgent action of renewed targeted public 
health promotion and HIV testing campaigns. 
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Introduction 
Infection caused by human immunodeficiency virus (HIV) is a major public health issue in 
former Soviet Union countries (1), including Estonia. With a population of 1.312 million (2), 
Estonia has experienced a rapidly expanding HIV epidemic among young people who inject 
drugs (PWID) with a rare HIV subtype CRF06_cpx from the year 2000, reaching the highest 
diagnosis rate in the European Union of 105.3 per 100,000 population in 2001 (3-5). Several 
efforts have been undertaken by the Estonian government to contain the rapidly evolving 
epidemic, including a campaign to increase people’s awareness of HIV infection, 
implementation of needle exchange programs, and offering free testing for all pregnant women, 
prisoners, as well as those with behavioural risks, together with the availability of free-of-
charge antiretroviral treatment for everyone (6, 7). By 2013, the rate of reported new diagnoses 
had decreased and stabilized at 24.6/100,000 (4, 8).  
Case reporting of HIV is well-established across Estonia and, since the first diagnosis of HIV 
in 1988, 9263 persons had been registered with the Estonian Health Board by the end of 2015. 
While injecting drug use was instrumental to the rise in new diagnoses, with 90% of cases in 
2000 among PWID, the number of diagnoses attributable to heterosexual contact gradually 
increased, overtaking that of PWID in 2010, and representing 46% of all cases in 2014 (4).   
Although these figures are important measures of the epidemic, they do not necessarily reflect 
current transmission patterns. This is important information as the ability to estimate current 
HIV incidence is an essential public health monitoring tool indicating the characteristics of 
individuals at greatest risk, and guiding prevention and intervention strategies.  
A number of serological tests have been developed which aim to differentiate recent from long-
standing HIV infection (9-13) and allow the development of methods to estimate incidence 
using blood at a single time point from the diagnostic HIV test (14-16). 
While data on HIV incidence in Western countries exist (14, 17), data for former Soviet Union 
countries, including Estonia, are limited (16).  We aimed to characterise the newly-diagnosed 
HIV-positive population in Estonia using the Recent HIV infection Testing Algorithm (RITA) 
in order to determine the proportion recently-infected and estimate HIV incidence using 
previously published methodologies (14, 18).   
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Methods 
HIV testing in Estonia 
An HIV test can be requested by any physician, including general practitioners, the cost of 
which is covered by health insurance with an estimated 90% of the population being insured. 
Additionally, there are 23 counselling offices, where people can self-select for an HIV test free 
of charge, as well as occasional field-testing campaigns. Primary tests are performed in 24 local 
laboratories using ELISA tests of various generations. All positive results are confirmed in a 
single HIV Reference Laboratory at West Tallinn Central Hospital using INNO-LIA® HIV I/II 
Score (INNOGENETICS N.V., Gent, Belgium), Bio-Rad's NEW LAV BLOT I (Bio-Rad 
Laboratories Inc, Hercules, California, USA) and NEW LAV BLOT II (Bio-Rad Laboratories 
Inc, Hercules, California, USA) tests, and reported to the Estonian Health Board. Screening for 
HIV antibodies is mandatory for blood and organ donors, for pregnant women at two time 
points during pregnancy, and is strongly recommended for patients with tuberculosis, as well 
as prison inmates.  
All HIV positive individuals linked to care are invited to participate in the Estonian HIV 
database (E-HIV, www.hiv.ut.ee) with signed informed consent as detailed elsewhere (8). 
Study population and design  
We conducted a prospective study using existing country-wide HIV testing services and 
included all individuals aged ≥18 years with newly-diagnosed HIV infection between 1st 
January 2013 and 31st December 2013. We linked test results from the Reference Laboratory 
to the Estonian Health Board database to obtain demographic data (sex, age, date of diagnosis, 
and reason for testing) using the unique Estonian national identification number (ID-code) 
Testing reasons were clinical signs, screening (pregnancy or blood donors), indicator diagnosis 
(STD, TB), indicator risk (intravenous drug usage, imprisonment, asymptomatic patient with 
known contact), other (pre-operation, patient will) or not known. Additional data on possible 
date of seroconversion, self-reported HIV transmission risk group, concomitant AIDS defining 
condition(s) (19), HIV-1 viral load and CD4+ cell count within 6 months of diagnosis, as well 
as information on the use of combination antiretroviral therapy (cART) were extracted form E-
HIV database. Finally, the laboratory databases of four main hospitals - Tartu University 
Clinics, West-Tallinn Central Hospital, Narva Hospital, and Ida-Viru Central Hospital were 
searched in April 2015 to identify previous negative HIV-1 antibody tests within 2 years of 
HIV diagnosis date, as well as HIV-1 viral load measurements within 6 months of diagnosis.  
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Laboratory methods 
All available left-over serum samples were obtained from the HIV Reference Laboratory of 
West Tallinn Central Hospital and tested for evidence of recent infection using the limiting 
antigen (LAg) avidity EIA assay (Sedia tm HIV-1 LAg Avidity EIA; Sedia Biosciences 
Corporation, Portland, OR, USA), according to the manufacturer’s protocol (20). LAg-avidity 
EIA is a single well antibody avidity-based incidence assay, presenting multi-subtype 
recombinant HIV-1 gp41 antigen. The antibody avidity, the bond between antigen and antibody 
after using M citrate buffer as dissociation agent, was measured as an optical density (ODn) 
value. The initial test requires samples to be screened, with samples with an ODn ≤2.0 tested 
in triplicate for confirmation and the median of three results being the final result. According 
to the 2013 protocol, ODn value <1.5 is classified as recent, and the respective median duration 
of an infection (recency period) is 130 (95% CI: 118-142) days (12, 20).   
As evaluations of the LAg avidity assay indicated that the assay performed poorly on 
specimens with a low or undetectable viral load and in persons receiving cART (13), samples 
with viral load <1000 copies/mL were reclassified as longstanding. All newly-diagnosed 
individuals were ART-naïve.  
Statistical methods 
HIV incidence was estimated using the stratified extrapolation method initially proposed by 
Karon et al and modified by Prejean et al (14, 18). Briefly, this modified method uses the 
observed number of recent infections, and the probability a person will present for an HIV test 
and be classified as recent using a RITA assay, to estimate the true number of infections within 
the population during the period of interest. The observed number of recent infections equates 
to the number of HIV-positive individuals testing for HIV and being assigned as recent by the 
LAg assay. To establish the true number of recent infections, the observed number is divided 
by the probability of testing and being classified as recent. 
Incidence calculations are described elsewhere (16). Rates were calculated by dividing the 
number of tests, diagnoses or estimated number of recent infections for the calendar year 2013 
by the Estonian population denominator and multiplied by 100,000 (21). Incidence rates were 
estimated for Estonia overall, and by age and sex using the general population estimates as 
denominators. We used published estimates of the number of PWID to derive incidence 
estimates for this subgroup (21). 
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Using a logistic regression model, we also examined factors associated with being recently 
infected with HIV. Variables included were: sex, age group, testing history, reason for test, and 
probable route of exposure. All confidence intervals (CI) are at the 95% significant level. 
Ethics statement 
The study was part of CASCADE within EuroCoord Network of Excellence 
(www.EuroCoord.net) funded by the European Union Framework Programme 7. The study 
was approved by the Research Ethics Committee of the University of Tartu and the Ethics 
Committee of University College London (UCL). E-HIV is approved by Estonian Data 
Protection Agency; all participants signed informed consent for participation in E-HIV.  
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Results 
Over the study period, 212,506 HIV tests were performed across Estonia corresponding to 
151,641 individuals aged ≥18 years. Of these, 82,526 were tested as part of screening (63,972 
blood donors and 18,554 antenatal screening) with 36 (11%) being newly diagnosed HIV 
positive and they were excluded from further analysis. In addition, 286 (89%) newly diagnosed 
adults were referred by a physician or self-selecting. 
Population characteristics 
The 286 individuals testing HIV positive equated to a crude diagnosis rate of 29.7 per 100,000 
population (40.5 for men and 20.7 for women). The median age at HIV diagnosis was 33 years 
(IQR: 28-42). Men accounted for 65% of new diagnoses, with the majority being tested within 
the capital Tallinn, and tested due to symptoms or high-risk behaviour (injecting drug use, 
imprisonment, or contact with a known HIV-positive individual). Self-reported risk factor 
information was available for 223 (78%), with the majority reporting sex between men and 
women (n=152; 68%). Of the 63 individuals without a recorded route of transmission, 46 (73%) 
were men. Two hundred and forty-two individuals (85%) had not undergone testing within last 
two years and were thus classified as first time testers (Table 1).  
CD4+ counts and HIV-1 viral loads were measured within a median of 10 days (IQR 5 - 38) 
of HIV diagnosis. Median CD4+ cell count was 367 (IQR 279-566) cells/µl among those 
recently infected and 362 (IQR 212-528) cells/µl among those with long-standing infection. 
Late presenters (CD4 count < 350 cells/µl) accounted for 32% of all newly-diagnosed 
individuals. Eleven individuals presented with AIDS at HIV diagnosis, and six with 
symptomatic seroconversion. Median HIV-1 viral load was 4.94 (IQR 4.26-5.65) log10 
copies/mL.  
The majority of the 224 sequenced samples (n= 180, 80%) were HIV-1 subtype CRF06_cpx. 
Recent HIV Infection 
Of the 286 individuals newly-diagnosed with HIV, 29 had insufficient serum for LAg testing. 
Of the remaining 257, a viral load measurement was available within 6 months of diagnosis for 
228 (80% of new diagnoses) as presented in Figure 1. Of these, 86 (38%) were classified as a 
recent infection according to the LAg assay, 4 of whom had a viral load <1000 copies/mL and 
were, therefore, reclassified as long-standing infection. Of 228 new diagnoses, 82 (36%) were, 
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thus, considered to have been recently-infected according to the LAg assay; 31% (n=62) among 
first-time testers and 67% (n=20) among repeat testers (Table 1).  
The median age of recently-infected individuals was 32 years [IQR: 26-41], with slightly more 
men than women (57% vs 43% respectively). All 44 (15%) individuals with a negative HIV 
test within one year prior to HIV diagnosis and 6 (2%) individuals presenting with symptomatic 
seroconversion tested recent with the LAg assay. 
The probability of testing and being classified as recent overall for repeat and first time testers 
and demographic characteristics are shown in Table 2. The only independent predictor for 
being recently-infected was being a repeat tester [Odds Ratio 3.96, 95% CI 1.66-9.46] 
compared to being a first time tester. 
HIV incidence estimates 
We estimated HIV incidence at 0.06% in 2013, corresponding to 642 new infections in that 
year (Table 3) and 12.8% were diagnosed among the non-screened population in the same year. 
Incidence was higher among younger age groups, and highest for age groups 18-29 (0.20%) 
and 30-39 years (0.22%). Incidence among men was substantially higher than among women 
in these two age groups (0.08% and 0.05%, respectively), and we estimated the highest 
incidence among PWID at 1.48%.    
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Discussion 
To the best of our knowledge this is the first study to estimate HIV incidence covering the 
entire population of an Eastern European country and using a RITA assay in a population 
infected predominantly with a recombinant HIV-1 subtype.  
We estimated HIV incidence for Estonia during 2013 to be 0.06%; higher than the 0.024% new 
diagnoses rate, and considerably higher than incidence estimates using the same methodology 
within Kiev, Ukraine (0.02%) (16); and the USA (0.019%) (14). The diagnosis rate for Estonia 
is in accordance with published estimates from previous years, and remains one of the highest 
rates of new HIV diagnoses in Europe (22, 23). The high incidence rate among PWID reported 
here of 1.48% is considerably higher than that reported previously by other investigators in the 
capital, Tallinn, of 0.02%, and likely reflects low success of preventive measures in this risk 
group (24).  
Estonia has a very similar HIV epidemic to Ukraine; both are among the highest rates of new 
diagnoses rates in Europe, despite obvious economic differences with gross national incomes 
per capita in 2014 of 3,760 USD for Ukraine compared to 19,010 USD for Estonia (25). 
National surveillance for both countries suggest that individuals at high risk of HIV are 
predominately PWID or heterosexuals, and not MSM. Interestingly, however, when persons 
self-reported their risk in Ukraine, 24% identified as MSM, who were also disproportionately 
affected by HIV (16), in contrast to the proportion of 2% in our study in Estonia. In an epidemic 
which is predominantly PWID and heterosexuals, one would expect similar HIV diagnoses 
rates among men and women. In our study the HIV diagnosis rate among men is almost double 
that of women's (40.5 vs 20.7). Still, men may be more likely than women to be drug injectors 
as shown in Estonia in 2000 when more than 80% of HIV infections occurred in young men 
(4). It may also be that men who are injecting drug users or at risk of heterosexual transmission 
are more likely to seek HIV testing than their female counterparts. We also noted, however, 
that 73% of the unknown risk group, a substantial proportion of all testers at 22%, are male, 
who were also more likely to be repeated testers and previous studies have reported that MSM 
are more likely to be repeated testers (26, 27). Taken together, these data may indicate that a 
significant proportion of men reporting risk factors other than MSM, as well as those with no 
reported risk, had acquired infection through sex with other men.   
Although several efforts have been made to increase the number of people testing for HIV, for 
example through the countrywide HIV testing guidelines which were introduced in 2012 (28), 
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we found that only 15% of those testing in 2013, and 25% of recent infections in that period, 
had previously tested for HIV, despite approximately 70,000 tests being performed that year, 
excluding screenings. We also found high percentage of recent infections (40%) and that a 
small percentage (12.8%) of estimated newly-infected individuals have been diagnosed, 
indicating that the risk population was being missed. Furthermore, we noted a high proportion 
of late presenters (32%) with median CD4 at diagnosis of 360 cells/µl, similar to late 
presentation rate reported by the investigators of western European cohorts of 38% and median 
CD4 count at diagnosis of 368 cells/µl (29). Given the high levels of viraemia which 
characterise undiagnosed HIV infection (30-32) and the risk of onward transmission (33, 34), 
as well as the higher risk of mortality and treatment failure for late presenters (35, 36), there is 
an urgent need to promote HIV testing in the at risk population to identify individuals close to 
the time of HIV infection and initiate cART.   
Having a previous negative test was the only predictor for presenting with a recent infection, 
suggesting that these persons are aware of their risk factors resulting in frequent tests. The risks 
of repeated testers need to be addressed. Surveillance of new diagnoses suggest that the number 
among PWID in Estonia has decreased, with diagnoses attributable to heterosexual contact 
crossing that of the number of PWID (4). However our estimates suggest that PWID remains 
an important population; incidence estimates among them being 24 times higher than the 
overall estimates.  
The main strength of our study is the overall design of the national surveillance in Estonia 
where individuals receive an ID-code which allows data from multiple sources to be linked 
successfully. As data are directly reported from the Reference Laboratory to the Health Board, 
we believe that all new diagnoses in Estonia in 2013 were captured. We also made every effort 
to use data on previous testing history by interrogating laboratory and clinical databases rather 
than relying on self-reporting which is a key element required to estimate incidence.  
Some limitations should be noted. First, we acknowledge that some individuals may have been 
tested during testing campaigns or in 23 counselling offices across country and their previous 
negative tests may, therefore, have not been recorded and would have under estimated the 
proportion of repeat testers. Such individuals are likely to be few in number, however and, in 
any case, would have been assigned to recent infection status by the LAg assay. Second, not 
all individuals newly diagnosed had viral load quantified at diagnoses. We were, however, able 
to link their records to viral load where the measurements undertaken within 6 months of the 
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HIV test; median time from diagnosis was 10 days. Thirdly, we were unable to estimate 
incidence for any HIV risk group other than PWID as general population figures are not 
available and/or the number testing positive whose HIV risk group was identified as MSM was 
very low. Finally, some uncertainties have been raised relating to the performance of the LAg 
assay in non-B HIV subtypes (37), and the prevalent subtype in Estonia, CRF06_cpx, has not 
been included into assay development (38). However, we found that all individuals with 
laboratory evidence of a negative HIV antibody test within 1 year prior to diagnosis were 
classified as recent, as were those diagnosed with seroconversion illness.  
In conclusion we demonstrate for the first time at a population level very high HIV-1 incidence 
in Estonia, especially among the young and PWID. There is clear indication of ongoing HIV 
transmission in all risk groups, with the possibility of undisclosed homosexuality in Estonia.  
All these findings need to be urgently addressed with improved implementation of preventive 
measures among appropriate risk groups and intensification of targeted HIV testing among the 
general population especially in the areas of concentrated HIV epidemic.  
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Figure 1. Incidence study flow chart in Estonia in 2013 
’ 
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Table 1: Characteristics of all newly-diagnosed* HIV-1 positive individuals in Estonia, 
January- December 2013 
Characteristics 
New HIV 
diagnoses 
Blood sample 
and viral load 
available 
Classified recent on 
LAg assay 
  n=286 n=228 n=82 % 
Age (years)         
 18-29 98 76 35 46 
 30-39 97 76 25 33 
 40-49 50 43 15 35 
 ≥50 39 32 7 22 
 Not reported 1 1     
Median age  (IQR) 33 (28-42) 34 (28-43) 32 (25-41)   
Sex         
 Male 185 145 47 32 
 Female 100 82 35 43 
 Not reported 1 1     
Self-reported route of 
exposure to HIV 
        
 Heterosexual men  79 61 19 31 
 Heterosexual women 73 60 26 43 
 PWID 65 54 25 46 
 MSM 6 5 1 20 
 Not reported 63 48 11 23 
Testing history         
 Repeat testers 44 30 20 67 
 First-time testers 242 198 62 31 
Reason for test         
 Clinical Indicators 95 76 29 38 
 High Risk Behaviour 78 62 27 44 
 Other 22 17 3 18 
 Not reported 91 73 23 32 
* does not include individuals testing positive through screening 
IQR= interquartile range, PWID= people who inject drugs, MSM= sex between men 
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Table 2. Direct estimation of probabilities of testing and being classified as recent by sub-
populations for Estonia 2013 
Characteristics Probability of testing and being classified as recent 
  
Repeat 
testers 
(95% CI) 
First-time 
testers 
(95% CI) 
All 0.360 0.306-0.414 0.136 0.111-0.163 
Age (years)         
 18-29 0.357 0.292-0.418 0.163 0.015-0.252 
 30-39 0.333 0.227-0.431 0.106 0.077-0.156 
 40-49 0.384 0.188-0.580 0.218 0.136-0.452 
 ≥50 0.524 0.200-0.841 0.089 0.054-0.163 
Sex         
 Male 0.399 0.321-0.483 0.142 0.111-0.192 
 Female 0.313 0.243-0.383 0.115 0.086-0.172 
Probable route of exposure        
 Heterosexual Contact 0.355 0.283-0.425 0.12 0.092-0.156 
 PWID 0.418 0.344-0.484 0.125 0.089-0.192 
 MSM -   -   
 Not reported 0.235 0.157-0.316 0.204 0.130-0.452 
 
CI= confidence intervals, PWID= people who inject drugs, MSM= Men who have sex with 
men 
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Table 3: HIV incidence estimates for Estonia, 2013 
    Population* 
Number new HIV 
infections (95% CI) 
% HIV incidence 
(95% CI) 
Total 1,076,483 642 (559-761) 0.06 (0.05-0.07) 
Age (years)      
 18-29 119,352 234 (172-311) 0.20 (0.14-0.26) 
 30-39 115,161 252 (189-333) 0.22 (0.16-0.29) 
 40-49 90,519 75 (46-115) 0.08 (0.05-0.13) 
 ≥50 751,451 73 (50-116) 0.01 (0.007-0.02) 
Sex      
 Male 490,847 376 (291-469) 0.08 (0.06-0.10) 
 Female 585,636 291 (224-364) 0.05 (0.04-0.06) 
Risk category of  
transmission 
    
 
Heterosexual 
contact 
NA 367 (308-454) NA 
 
  PWID 14,000 207 (143-282) 1.48 (1.02-2.01) 
Source:  (*) Statistics Estonia 2016 
CI= confidence intervals, PWID= people who inject drugs 
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Appendix 
CASCADE Steering Committee: Julia Del Amo (Chair), Laurence Meyer (Vice Chair), 
Heiner C. Bucher, Geneviève Chêne, Osamah Hamouda, Deenan Pillay, Maria Prins, Magda 
Rosinska, Caroline Sabin, Giota Touloumi. 
CASCADE Co-ordinating Centre: Kholoud Porter (Project Leader), Annabelle Gourlay, 
Andrea Cartier, Lorraine Fradette, Sarah Walker, Abdel Babiker.  
CASCADE Clinical Advisory Board: Heiner C. Bucher, Andrea De Luca, Martin Fisher, 
Roberto Muga 
CASCADE Collaborators: Australia PHAEDRA cohort (Tony Kelleher, David Cooper, 
Robert Finlayson, Mark Bloch) Sydney AIDS Prospective Study and Sydney Primary HIV 
Infection cohort (Tony Kelleher, Tim Ramacciotti, Linda Gelgor, David Cooper, Don Smith); 
Austria Austrian HIV Cohort Study (Robert Zangerle); Canada South Alberta clinic (John 
Gill); Estonia Tartu Ülikool (Irja Lutsar); France ANRS CO3 Aquitaine cohort (Linda 
Wittkop, Francois Dabis, Rodolphe Thiebaut), ANRS CO4 French Hospital Database 
(Dominique Costagliola, Marguerite Guiguet), Lyon Primary Infection cohort (Philippe 
Vanhems), French ANRS CO6 PRIMO cohort (Marie-Laure Chaix, Jade Ghosn), ANRS CO2 
SEROCO cohort (Laurence Meyer, Faroudy Boufassa); Germany German HIV-1 
seroconverter cohort (Osamah Hamouda, Claudia Kücherer, Barbara Bartmeyer); Greece 
AMACS (Helen Sambatakou, Nikolaos V Sipsas, Charalambos A Gogos); Greek Haemophilia 
cohort (Giota Touloumi, Nikos Pantazis, Olga Katsarou); Italy Italian Seroconversion Study 
(Giovanni Rezza, Maria Dorrucci), ICONA cohort (Antonella d’Arminio Monforte, Andrea 
De Luca.) Netherlands Amsterdam Cohort Studies among homosexual men and drug users 
(Maria Prins, Ronald Geskus, Jannie van der Helm, Hanneke Schuitemaker); Norway Oslo 
and Ulleval Hospital cohorts (Mette Sannes, Oddbjorn Brubakk, Anne-Marte Bakken Kran, 
Anne Margarita Dyrhol Riise); Poland National Institute of Hygiene (Magdalena Rosinska); 
Spain Badalona IDU hospital cohort (Roberto Muga, Jordi Tor), Barcelona IDU Cohort 
(Patricia Garcia de Olalla, Joan Cayla), CoRIS-scv (Julia del Amo, Santiago Moreno, Susana 
Monge); Madrid cohort (Julia Del Amo, Jorge del Romero), Valencia IDU cohort (Santiago 
Pérez-Hoyos); Sweden Swedish InfCare HIV Cohort, Sweden (Anders Sönnerborg); 
Switzerland Swiss HIV Cohort Study (Heiner C. Bucher, Huldrych Günthard, Martin 
Rickenbach); Ukraine Perinatal Prevention of AIDS Initiative (Ruslan Malyuta); United 
Kingdom Public Health England (Gary Murphy), UK Register of HIV Seroconverters 
(Kholoud Porter, Anne Johnson, Andrew Phillips, Abdel Babiker), University College London 
(Deenan Pillay); African cohorts: Genital Shedding Study (US: Charles Morrison; Family 
Health International, Robert Salata, Case Western Reserve University, Uganda: Roy Mugerwa, 
Makerere University, Zimbabwe: Tsungai Chipato, University of Zimbabwe); International 
AIDS Vaccine Initiative (IAVI) Early Infections Cohort (Kenya, Rwanda, South Africa, 
Uganda, Zambia: Pauli N. Amornkul, IAVI, USA; Jill Gilmour, IAVI, UK; Anatoli Kamali, 
Uganda Virus Research Institute/Medical Research Council Uganda; Etienne Karita, Projet 
San Francisco, Rwanda). 
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EuroCoord Executive Board: Fiona Burns, University College London, UK; Geneviève 
Chêne (Chair), University of Bordeaux, France; Dominique Costagliola (Scientific 
Coordinator), Institut National de la Santé et de la Recherche Médicale, France; Carlo 
Giaquinto, Fondazione PENTA, Italy; Jesper Grarup, Region Hovedstaden, Denmark; Ole 
Kirk, Region Hovedstaden, Denmark; Laurence Meyer, Institut National de la Santé et de la 
Recherche Médicale, France; Heather Bailey, University College London, UK; Alain Volny 
Anne, European AIDS Treatment Group, France; Alex Panteleev, St. Petersburg City AIDS 
Centre, Russian Federation; Andrew Phillips, University College London, UK, Kholoud 
Porter, University College London, UK; Claire Thorne, University College London, UK. 
EuroCoord Council of Partners: Jean-Pierre Aboulker, Institut National de la Santé et de la 
Recherche Médicale, France; Jan Albert, Karolinska Institute, Sweden; Silvia Asandi , 
Romanian Angel Appeal Foundation, Romania; Geneviève Chêne, University of Bordeaux, 
France; Dominique Costagliola, INSERM, France; Antonella d’Arminio Monforte, ICoNA 
Foundation, Italy; Stéphane De Wit, St. Pierre University Hospital, Belgium; Peter Reiss, 
Stichting HIV Monitoring, Netherlands; Julia Del Amo, Instituto de Salud Carlos III, Spain; 
José Gatell, Fundació Privada Clínic per a la Recerca Bíomèdica, Spain; Carlo Giaquinto, 
Fondazione PENTA, Italy; Osamah Hamouda, Robert Koch Institut, Germany; Igor Karpov, 
University of Minsk, Belarus; Bruno Ledergerber, University of Zurich, Switzerland; Jens 
Lundgren, Region Hovedstaden, Denmark; Ruslan Malyuta (Chair), Perinatal Prevention of 
AIDS Initiative, Ukraine; Claus Møller, Cadpeople A/S, Denmark; Kholoud Porter, University 
College London, United Kingdom; Maria Prins, Academic Medical Centre, Netherlands; Aza 
Rakhmanova, St. Petersburg City AIDS Centre, Russian Federation; Jürgen Rockstroh, 
University of Bonn, Germany; Magda Rosinska, National Institute of Public Health, National 
Institute of Hygiene, Poland; Manjinder Sandhu, Genome Research Limited; Claire Thorne, 
University College London, UK; Giota Touloumi, National and Kapodistrian University of 
Athens, Greece; Alain Volny Anne, European AIDS Treatment Group, France.  
EuroCoord External Advisory Board: David Cooper, University of New South Wales, 
Australia; Nikos Dedes, Positive Voice, Greece; Kevin Fenton, Public Health England, USA; 
David Pizzuti, Gilead Sciences, USA; Marco Vitoria, World Health Organisation, Switzerland.  
EuroCoord Secretariat: Silvia Faggion, Fondazione PENTA, Italy; Lorraine Fradette, 
University College London, UK; Richard Frost, University College London, UK; Andrea 
Cartier, University College London, UK; Dorthe Raben, Region Hovedstaden, Denmark; 
Christine Schwimmer, University of Bordeaux, France; Martin Scott, UCL European Research 
& Innovation Office, UK.  
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